Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Multiple myeloma: highlights at ASH 2020

Sergio Giralt • 14 Dec 2020
ASH 2020
Multiple Myeloma Carfilzomib Cyclophosphamide Dexamethasone Lenalidomide
FORTE

Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses some of the highlights in multiple myeloma presented at ASH 2020. The impact of measurable residual disease (MRD) on patient outcomes is discussed, as well as the importance of using MRD as a way of evaluating treatments in the future. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Amgen, Janssen, Celgene, Quintiles, Pfizer, CSL Behring, Sanof, Adienne, Kite, JAZZ, Actinuum

More from Sergio Giralt

0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:12
An update in cellular therapies: gene editing for SCD and immunotherapies for MM
Sergio Giralt • 8 Dec 2023
0:59
The role of radioimmunoconjugates in AML treatment: insights from the SIERRA trial
Sergio Giralt • 8 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals